Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 615285, 4 pages
http://dx.doi.org/10.1155/2015/615285
Research Article

Effects of Green Tea Extracts on the Pharmacokinetics of Quetiapine in Rats

1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
2Bioavailability Laboratory, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
3Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Received 2 October 2014; Accepted 29 December 2014

Academic Editor: Alvin J. Beitz

Copyright © 2015 Essam Ezzeldin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Khan and H. Mukhtar, “Tea polyphenols for health promotion,” Life Sciences, vol. 81, no. 7, pp. 519–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. C. S. Yang, X. Wang, G. Lu, and S. C. Picinich, “Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance,” Nature Reviews Cancer, vol. 9, no. 6, pp. 429–439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Clement, “Can green tea do that? A literature review of the clinical evidence,” Preventive Medicine, vol. 49, no. 2-3, pp. 83–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Johnson, H. H. Bailey, and H. Mukhtar, “Green tea polyphenols for prostate cancer chemoprevention: a translational perspective,” Phytomedicine, vol. 17, no. 1, pp. 3–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Katiyar, C. A. Elmets, and S. K. Katiyar, “Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair,” The Journal of Nutritional Biochemistry, vol. 18, no. 5, pp. 287–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Melgarejo, J. L. Urdiales, F. Sánchez-Jiménez, and M. Á. Medina, “Targeting polyamines and biogenic amines by green tea epigallocatechin-3-gallate,” Amino Acids, vol. 38, no. 2, pp. 519–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Moore, K. G. Jackson, and A. M. Minihane, “Green tea (Camellia sinensis) catechins and vascular function,” British Journal of Nutrition, vol. 102, no. 12, pp. 1790–1802, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Jodoin, M. Demeule, and R. Béliveau, “Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1542, no. 1–3, pp. 149–159, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Misaka, K. Kawabe, S. Onoue et al., “Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes,” Drug Metabolism and Pharmacokinetics, vol. 28, no. 3, pp. 244–249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Roth, B. N. Timmermann, and B. Hagenbuch, “Interactions of green tea catechins with organic anion-transporting polypeptides,” Drug Metabolism and Disposition, vol. 39, no. 5, pp. 920–926, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Colalto, “Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment,” Pharmacological Research, vol. 62, no. 3, pp. 207–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. I. Netsch, H. Gutmann, C. B. Schmidlin, C. Aydogan, and J. Drewe, “Induction of CYP1A by green tea extract in human intestinal cell lines,” Planta Medica, vol. 72, no. 6, pp. 514–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L.-C. Lin, M.-N. Wang, and T.-H. Tsai, “Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38,” Chemico-Biological Interactions, vol. 174, no. 3, pp. 177–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Misaka, K. Kawabe, S. Onoue et al., “Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats,” Drug Metabolism and Pharmacokinetics, vol. 28, no. 6, pp. 514–518, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Misaka, N. Miyazaki, T. Fukushima, S. Yamada, and J. Kimura, “Effects of green tea extract and (-)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats,” Phytomedicine, vol. 20, no. 14, pp. 1247–1250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Nishikawa, N. Ariyoshi, A. Kotani et al., “Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam,” Drug Metabolism and Pharmacokinetics, vol. 19, no. 4, pp. 280–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-C. Shin and J.-S. Choi, “Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats,” Anti-Cancer Drugs, vol. 20, no. 7, pp. 584–588, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Qiao, C. Gu, W. Shang et al., “Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro,” Food and Chemical Toxicology, vol. 49, no. 6, pp. 1410–1415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. E. H. Jang, J. Y. Choi, C. S. Park et al., “Effects of green tea extract administration on the pharmacokinetics of clozapine in rats,” Journal of Pharmacy and Pharmacology, vol. 57, no. 3, pp. 311–316, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Li and J.-S. Choi, “Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats,” Die Pharmazie, vol. 63, no. 11, pp. 815–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Chiesa, F. Chierzi, D. De Ronchi, and A. Serretti, “Quetiapine for bipolar depression: a systematic review and meta-analysis,” International Clinical Psychopharmacology, vol. 27, no. 2, pp. 76–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. C. Altamura, L. Lietti, C. Dobrea, B. Benatti, C. Arici, and B. Dell'Osso, “Mood stabilizers for patients with bipolar disorder: the state of the art,” Expert Review of Neurotherapeutics, vol. 11, no. 1, pp. 85–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Vieta, J. Locklear, O. Günther et al., “Treatment options for bipolar depression: a systematic review of randomized, controlled trials,” Journal of Clinical Psychopharmacology, vol. 30, no. 5, pp. 579–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Lindsay DeVane and C. B. Nemeroff, “Clinical pharmacokinetics of quetiapine: an atypical antipsychotic,” Clinical Pharmacokinetics, vol. 40, no. 7, pp. 509–522, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. Agency HoM, “Public assessment report on quitiapine fumarate,” DE/H/1458-1459/001-004/DC Quetiapine, Heads of Medicines Agency, Langen, Germany, 2009. View at Google Scholar
  26. Y. W. J. Wong, C. Yeh, and P. T. Thyrum, “The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine,” Journal of Clinical Psychopharmacology, vol. 21, no. 1, pp. 89–93, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. H. R. Winter, C. L. DeVane, C. Figueroa et al., “Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder,” Human Psychopharmacology, vol. 22, no. 7, pp. 469–476, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. W. Grimm, N. M. Richtand, H. R. Winter, K. R. Stams, and S. B. Reele, “Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics,” British Journal of Clinical Pharmacology, vol. 61, no. 1, pp. 58–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Moons, M. de Roo, S. Claes, and G. Dom, “Relationship between P-glycoprotein and second-generation antipsychotics,” Pharmacogenomics, vol. 12, no. 8, pp. 1193–1211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. G. V. Bakken, E. Molden, K. Knutsen, N. Lunder, and M. Hermann, “Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro,” Drug Metabolism and Disposition, vol. 40, no. 9, pp. 1778–1784, 2012. View at Publisher · View at Google Scholar · View at Scopus